Show simple item record

dc.contributor.authorLópez de Maturana, Rakel
dc.contributor.authorLang, Valérie
dc.contributor.authorZubiarrain, Amaia
dc.contributor.authorSousa, Amaya
dc.contributor.authorVázquez, Nerea
dc.contributor.authorGorostidi, Ana
dc.contributor.authorÁguila, Julio
dc.contributor.authorLópez de Munain Arregui, Adolfo José
dc.contributor.authorRodríguez, Manuel
dc.contributor.authorSánchez-Pernaute, Rosario
dc.date.accessioned2019-04-09T12:42:48Z
dc.date.available2019-04-09T12:42:48Z
dc.date.issued2016-11-18
dc.identifier.citationJournal of Neuroimflammation 13 : (2016) // Article ID 295es_ES
dc.identifier.issn1742-2094
dc.identifier.urihttp://hdl.handle.net/10810/32385
dc.description.abstractBackground: Mutations in leucine-rich repeat kinase 2 (LRRK2) contribute to both familial and idiopathic forms of Parkinson's disease (PD). Neuroinflammation is a key event in neurodegeneration and aging, and there is mounting evidence of LRRK2 involvement in inflammatory pathways. In a previous study, we described an alteration of the inflammatory response in dermal fibroblasts from PD patients expressing the G2019S and R1441G mutations in LRRK2. Methods: Taking advantage of cellular reprogramming, we generated induced pluripotent stem cell (iPSC) lines and neurons thereafter, harboring LRRK2G2019S and LRRK2R1441G mutations. We used gene silencing and functional reporter assays to characterize the effect of the mutations. We examined the temporal profile of TNF alpha-induced changes in proteins of the NF-kappa B pathway and optimized western blot analysis to capture alpha-synuclein dynamics. The effects of the mutations and interventions were analyzed by two-way ANOVA tests with respect to corresponding controls. Results: LRRK2 silencing decreased alpha-synuclein protein levels in mutated neurons and modified NF-kappa B transcriptional targets, such as PTGS2 (COX-2) and TNFAIP3 (A20). We next tested whether NF-kappa B and alpha-synuclein pathways converged and found that TNF alpha modulated alpha-synuclein levels, although we could not detect an effect of LRRK2 mutations, partly because of the individual variability. Nevertheless, we confirmed NF-kappa B dysregulation in mutated neurons, as shown by a protracted recovery of I kappa B alpha and a clear impairment in p65 nuclear translocation in the LRRK2 mutants. Conclusions: Altogether, our results show that LRRK2 mutations affect alpha-synuclein regulation and impair NF-kappa B canonical signaling in iPSC-derived neurons. TNFa modulated alpha-synuclein proteostasis but was not modified by the LRRK2 mutations in this paradigm. These results strengthen the link between LRRK2 and the innate immunity system underscoring the involvement of inflammatory pathways in the neurodegenerative process in PDes_ES
dc.description.sponsorshipThis study is funded by grants from the Spanish Ministry of Economy and Competitiveness (MINECO), Fondo de Investigaciones Sanitarias PI15/00486, the European Commission FP7 Health -278871, and the Joint Program in Neurodegenerative Diseases AC 14/0041 (DAMNDPATHS) to RSP.es_ES
dc.language.isoenges_ES
dc.publisherBiomed Centrales_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/ PI15/00486es_ES
dc.relationinfo:eu-repo/grantAgreement/EC/FP7/278871es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectParkinson's diseasees_ES
dc.subjectLRRK2es_ES
dc.subjectinflammationes_ES
dc.subjectiPSCses_ES
dc.subjectNF-kappa Bes_ES
dc.subjectalpha-Synucleines_ES
dc.subjectdopamine neuronses_ES
dc.subjectinhibitiones_ES
dc.subjectphosphorylationes_ES
dc.subjectinclusionses_ES
dc.subjectexpressiones_ES
dc.subjectinterplayes_ES
dc.subjectautophagyes_ES
dc.subjectdementiaes_ES
dc.titleMutations in LRRK2 impair NF-κB pathway in iPSC-derived neuronses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holderThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-016-0761-xes_ES
dc.identifier.doi10.1186/s12974-016-0761-x
dc.departamentoesNeurocienciases_ES
dc.departamentoeuNeurozientziakes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Except where otherwise noted, this item's license is described as This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.